The synthesis of influenza virus mRNA is primed by capped (m 7 GpppNm-) short RNAs that are cleaved from RNA polymerase II transcripts by a virally encoded endonuclease. This cap-dependent endonuclease activity called "cap-snatching" may provide a unique target for novel anti-viral agents. To screen candidate inhibitors, it is essential to establish a method for producing efficiently a capped RNA substrate and a convenient assay for the cap-snatching activity. A 3 -biotinylated short RNA was prepared by in vitro transcription, purified by C 18 reverse-phase column chromatography, and subjected to a capping reaction involving three recombinant capping enzymes. This capped RNA was shown to be an efficient substrate for the cap-snatching assay. Cap-snatching activity was then measured with the novel pull-down assay developed in this study, which is based on the streptavidin-biotin interaction. A known inhibitor for the cap-snatching reaction was evaluated by the pull-down assay, demonstrating the efficacy of the established screening system.
Introduction
Influenza virus causes acute respiratory infections in humans that sometimes progress to severe pulmonary diseases, resulting in considerable mortality among elderly and other high-risk individuals. Because the currently available vaccines do not protect completely against influenza virus infections, there is an urgent need for the development of anti-influenza therapeutic agents. There are currently only two kinds of licensed drugs for influenza virus, neuraminidase inhibitors (oseltamivir and zanamivir) and M2 channel blockers (amantadine and rimantadine) (De Clercq, 2006; Salomon and Webster, 2009; Das et al., 2010; Das, 2012) . However, many influenza type A virus strains have become resistant to these M2 channel blockers and/or neuraminidase inhibitors (Hayden et al., 1989; Bright et al., 2005; Le et al., 2005) .
The influenza virus genome consists of eight segmented RNA molecules with negative polarity. The single-stranded genomic RNAs are transcribed and replicated by a virally encoded RNAdependent RNA polymerase, which is composed of three subunits, PB1, PB2, and PA (Horisberger, 1980) . The translation of the viral mRNAs by host ribosomes requires that the mRNAs are capped, to allow their recognition and binding. However, influenza virus RNA polymerase does not carry the enzymatic activities required to add a 5 cap to its own mRNAs, so the necessary cap structure is "snatched" from host pre-mRNA transcripts (Bouloy et al., 1978 (Bouloy et al., , 1980 Plotch et al., 1981; Ulmanen et al., 1981) . Influenza virus RNA polymerase binds to the host pre-mRNA transcripts through their cap structures and cleaves them to generate capped RNAs of 11-13 nucleotides, which are used as the primers for viral transcription (Bouloy et al., 1978 (Bouloy et al., , 1980 Plotch et al., 1981; Ulmanen et al., 1981) . This cap-snatching reaction may be used as a novel target for the development of anti-influenza-virus agents because this reaction is a unique and essential mechanism for influenza virus transcription.
In eukaryotes, most cellular and viral mRNAs have 5 cap structures consisting of 7-methylguanosine linked to the initiating nucleotide of the transcripts via an inverted 5 -5 triphosphate bridge (m 7 G(5 )ppp(5 )N; Cap 0) (Banerjee, 1980; Mizumoto and Kaziro, 1987; Furuichi and Shatkin, 2000; Decroly et al., 2011) . The Cap 0 structure is essential for the growth of Saccharomyces cerevisiae (Shibagaki et al., 1992; Mao et al., 1995) and the survival of mammalian cells (Yue et al., 1997) . The Cap 0 structure is further methylated at 2 -O-ribose, either at the first nucleotide (m 7 G(5 )ppp(5 )Nm; Cap 1) or at the first and second nucleotides (m 7 G(5 )ppp(5 )NmNm; Cap 2) in higher eukaryotes by nucleoside 2 -O-methyltransferases (Banerjee, 1980; Furuichi and Shatkin, 2000) .
The Cap 0 structure is formed by three enzymatic reactions: (1) RNA 5 -triphosphatase (TPase) hydrolyzes the 5 triphosphate end of the pre-mRNA to a diphosphate; (2) mRNA guanylyltransferase (GTase) adds a guanosine monophosphate (GMP) residue to the diphosphate end of the RNA; and (3) m 7 G-methyltransferase (m 7 G-MTase) methylates GpppN-to form the Cap 0 structure (Banerjee, 1980; Mizumoto and Kaziro, 1987; Furuichi and Shatkin, 2000; Decroly et al., 2011) . These three enzymes are present in the virion of vaccinia virus, reovirus, and cytoplasmic polyhedrosis virus (Shuman et al., 1980) . Vaccinia virus also uses cap1 mRNA nucleoside 2 -O-methyltransferase (cap1 MTase) to convert Cap 0 to the Cap 1 structure (Schnierle et al., 1992) . Many cellular capping enzymes and m 7 G-MTase have also been isolated from humans (hCap1, hMet1) (Tsukamoto et al., 1998a,b; Yamada-Okabe et al., 1998) , mice (Mce1) (McCracken et al., 1997) , Caenorhabditis elegans (CEL-1) (Takagi et al., 1997) , S. cerevisiae (CEG1, CET1, ABD1) (Shibagaki et al., 1992; Mao et al., 1995; Tsukamoto et al., 1997) , and Schizosaccharomyces pombe (Pce1, Pct1) (Shuman et al., 1994; Pei et al., 2001) . Recently, human cap1 mRNA (nucleoside-2 -O-)-methyltransferase (hMTr1) (Belanger et al., 2010) and cap2 mRNA (nucleoside-2 -O-)-methyltransferase (hMTr2) (Werner et al., 2011) were identified.
The influenza type A virus RNA polymerase cleaves preferentially RNA with 5 Cap 1 over that with Cap 0, but not RNA with an unmethylated core cap (Wakai et al., 2011) . The RNA polymerase from the type B virus shows similar substrate specificity, with the exception that the type B RNA polymerase also cleaves RNA with an unmethylated core cap (Wakai et al., 2011) . Consistent with this, the in vitro transcription activity of influenza virus is stimulated more by mRNA methylated at 2 -O-ribose residues than by mRNA lacking 2 -O-ribose methylation (Bouloy et al., 1980) . Therefore, it is necessary to establish a procedure to prepare an RNA substrate with the Cap 1 structure for the development of a screening system for anti-cap-snatching agents.
To date, only a few studies have described an inhibitor of capsnatching activity (Tomassini et al., 1994 (Tomassini et al., , 1996 Hsu et al., 2012) . In these studies, the mRNA of alfalfa mosaic virus RNA 4 was first decapped in vitro, and then capped using enzymes purified from vaccinia virus to prepare the substrate. However, this complicated substrate preparation procedure and the heterogeneity of the natural RNA might hinder the efficient screening of candidate compounds.
During biochemical and molecular biological studies of the capping enzymes, we purified these enzymes from various sources, including mammalian cells, brine shrimp, and yeast, analyzed the biochemical mechanism of cap formation (reviewed in Mizumoto and Kaziro, 1987) , and cloned the genes of these enzymes from humans (Tsukamoto et al., 1998a,b) and yeast (Shibagaki et al., 1992; Tsukamoto et al., 1997) . Based on these studies, a novel method to produce a short Cap 1-RNA with 3 -biotinylation and a convenient streptavidin-biotin-based pull-down assay for screening anti-influenza-virus compounds that target the viral capsnatching activity have been developed in this study. An RNA oligonucleotide with biotinylated uridine monophosphate (UMP) at its 3 end was synthesized by in vitro transcription using T7 RNA polymerase, and was separated from any prematurely terminated products by C 18 reverse-phase column chromatography. The Cap 1 structure was added to the full-length RNA with an efficiency of over 95% using three recombinant capping enzymes. This capped RNA was shown to be an efficient substrate for the influenza virus cap-snatching activity. A known inhibitor of the cap-snatching reaction (Tomassini et al., 1994) could be evaluated with this system, demonstrating the efficacy of the system for the screening of antiviral compounds. (Shuman, 1990) ), genomic DNA from S. cerevisiae NN1 (Yamagishi et al., 1995) , and the genomic DNA of vaccinia virus WTF7-3 (kindly provided by Dr. T. Nakayama [Kitasato Institute for Life Sciences, Japan]), respectively, using following primers: D1N, D1Nf (5 -GGCATATGGATGCCAACGTAGTATC-3 ) and D1Nr (5 -GGAAGCTTAATCCGATAGTTTATCCTC-3 ); ABD1, yABDf (5 -CCAGTGCATATGTCAACCAAACCAG-3 ) and yABDr (5 -CCCGGATCCTCAGTTGGGCTTTACGC-3 ); VP39, VP39f (5 -GGCATATGGATGTTGTGTCGTTAGATAAACC-3 ) and VP39r (5 -CCGGATCCTTATTTATTACCGCGTACGGATCTC-3 ). The amplified fragments were digested with appropriate restriction enzymes (D1N, Nde I and Hind III; ABD1, Nde I and BamH I; VP39, Nde I and BamH I) and inserted into correspondingly digested pT7-7(His) . The resultant plasmids, pHis(T)-D1N(1-536), pHis(T)-ABD1, and pHis(T)-VP39, respectively, were introduced into Escherichia coli BL21(DE3)pLysS (Studier et al., 1990) . The transformed cells were grown in LB medium containing 50 g/ml ampicillin at 25 • C. When OD 600 reached 1.0, protein expression was induced with isopropylthiogalactoside (0.5 mM) and the cells were harvested after 5 h in culture at 25 • C.
Materials and methods

Influenza virus
The E. coli pellet (3 g) was suspended in 40 ml of lysis buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 5 mM 2-mercaptoethanol, 0.2 mM EDTA, 10% glycerol, 1 mM phenylmethanesulfonyl fluoride) and 0.5% Triton X-100. After lysis by sonication and clarification by centrifugation, the supernatant was applied to Ni + -NTA agarose (Qiagen, Germany). The column was eluted with a gradient of imidazole (20-300 mM) in Buffer A (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 5 mM 2-mercaptoethanol, and 10% glycerol). D1N, ABD1, and VP39 were eluted at around 100 mM, 100-200 mM, and 100-150 mM imidazole, respectively. The fractions containing the recombinant enzymes were pooled, dialyzed against Buffer B (20 mM Tris-HCl [pH 7.0], 20 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol), and applied to a High-Trap SP Sepharose FPLC column (∅ 0.4 cm × 2 cm; Amersham Biosciences, Sweden). The column was eluted with a linear gradient of NaCl (0.05-1.0 M) in Buffer B. D1N, ABD1, and VP39 were eluted at 200-300 mM, 300-400 mM, and 400-500 mM NaCl, respectively. The fractions containing the recombinant enzymes were pooled, dialyzed against Buffer C (20 mM HEPES-Na [pH 7.9], 1 mM EDTA, 100 mM NaCl, 1 mM DTT, and 50% glycerol), and stored in aliquots at −80 • C until use.
Synthesis of biotinylated Cap 1-RNA (m 7 GpppGm-RNA)
A triphosphate-ended RNA (32 nucleotides: 5 -GAACAACAA-AAAAAACAACCAACAACCAAAU-biotin-3 ), designated "GACU 32 -biot", was synthesized using T7 RNA polymerase (Ambion, USA) with synthetic DNA as the template (template strand, 5 -ATTT-GGTTGTTGGTTGTTTTTTTTGTTCTTCTATAGTGAGTCGTATTAAGCTT-3 ; coding strand, 5 -AAGCTTAATACGACTCACTATAGAA-3 ; underlined sequences are complementary). For in vitro transcription, 100 l of a solution containing 40 mM Tris-HCl (pH 8.0), 12 mM MgCl 2 , 1 mM spermidine, 0.05% Triton X-100, 5 mM DTT, 2 mM ATP, 2 mM CTP, 0.25 mM [␣-32 P]GTP (400 cpm/pmol; Institute of Isotopes, Hungary), 0.5 mM biotin-16-UTP (Epicentre, USA), 20 pmol of template DNA, and 500 U of T7 RNA polymerase was incubated at 37 • C for 3 h. After the reaction, 1 ml of 50 mM ammonium bicarbonate (pH 8.0) was added and the sample was loaded onto a C 18 reverse-phase cartridge column (InertSep SlimJ C 18 , 500 mg; GL Science, Japan). The column was washed twice with 5 ml of 50 mM ammonium bicarbonate (pH 8.0) and three times with 1 ml of 50 mM ammonium bicarbonate (pH 8.0) containing 2% CH 3 CN. GACU 32 -biot was eluted with a stepwise increase in the CH 3 CN concentration from 4% to 10% in 50 mM ammonium bicarbonate (pH 8.0). Each fraction was analyzed by 7 M urea/18% polyacrylamide gel electrophoresis, and the fractions containing GACU 32 -biot but no prematurely terminated products were pooled, lyophilized, and subjected to the next capping reaction.
GACU 32 -biot was capped as described previously with recombinant enzymes, as follows. GACU 32 -biot (50 pmol) was incubated with vaccinia virus D1N (0.5 g), yeast ABD1 (1.5 g), vaccinia virus VP39 (1.8 g), and 10 M [␣-32 P]GTP (2 × 10 5 cpm/pmol) at 37 • C for 2 h in a reaction mixture (100 l) containing 40 mM Tris-HCl (pH 7.9), 1.5 mM MgCl 2 , 40 mM NaCl, 5 mM DTT, 0.1 mM S-adenosyl-l-methionine, 0.2 mg/ml bovine serum albumin, and 80 U of RNase inhibitor (Takara, Japan). After the reaction, the capped RNA was extracted with phenol-chloroform, precipitated with ethanol, and dissolved in 2% CH 3 CN.
To confirm the cap structure on GACU 32 -biot (5 -terminally labeled with [␣-32 P]GTP (400 cpm/pmol)), nonradioactive GTP was used in the capping reaction, and the cap structure was liberated by digestion with nuclease P1 (Wako Pure Chemical Industries, Japan) (Belanger et al., 2010) . The product was analyzed by polyethyleneimine-cellulose thin-layer chromatography (PEI-CEL UV 254 ; Macherey-Nagel, Germany) with 0.3 M (NH 4 ) 2 SO 4 as a solvent and visualized by FLA-7000 fluorescent image analyzer (Fuji Film, Japan).
Assays for influenza virus endonuclease (cap-snatching) activity
Cap-snatching activity was measured in a reaction mixture (25 l) containing 50 mM Tris-HCl (pH 7.9), 0.1 M ammonium acetate, 1.5 mM MgCl 2 , 2.5 mM DTT, 0.1% Nonidet P-40, 4 U of RNasin, 30-50 fmol [ 32 P]Cap 1-GACU 32 -biot (2 × 10 5 cpm/pmol), and the indicated amount of influenza virus A virions. The samples were incubated at 37 • C for 1 h. After the reaction, halves of the products were extracted with phenol-chloroform, precipitated with ethanol, and analyzed with 18% polyacrylamide gel electrophoresis in the presence of 7 M urea (Klumpp et al., 2001; Wakai et al., 2011) . The RNAs were visualized by autoradiography or analyzed with an FLA-7000 fluorescent image analyzer. Endonuclease activity is expressed as a ratio of the cleaved RNA to the total capped RNA.
The remaining halves of the samples were mixed with 200 l of stop solution (20 mM Tris-HCl [pH 8.0], 5 mM EDTA, and 150 mM NaCl) containing 30 g of Dynabeads ® M-280 Streptavidin (Dynal, Norway) for 10 min at room temperature. The mixtures were poured onto 200 l pipette tips the ends of which were filled with a small piece of GF/C glass filter (Whatman, UK). Each tip was placed in a 2 ml tube with an adapter for a centrifuge (Glygen, USA), and centrifuged at 2000 × g for 2 min. The Dynabead-bound and Fig. 1 . A schematic illustration of synthesis of Cap 1-RNA with 3 -biotinylation. A 32-base RNA with 3 -biotinylation (GACU32-biot) was synthesized by in vitro transcription from a synthetic DNA template, using T7 RNA polymerase, [␣- 32 P]GTP (400 cpm/pmol), ATP, CTP, and biotin-16-UTP. After purification by reverse-phase column chromatography, the radioactive Cap 1 structure (2 × 10 5 cpm/pmol) was added to GACU32-biot in sequential reactions with vaccinia virus D1N, S. cerevisiae ABD1, and vaccinia virus VP39. The small and large asterisks indicate the radioactive phosphates (400 cpm/pmol and 2 × 10 5 cpm/pmol, respectively) in the Cap 1 structure.
unbound fractions were quantified separately by measuring the Cerenkov radiation, and the ratio of cleaved RNA to total capped RNA was calculated.
Results
3.1. Synthesis and purification of a short RNA with 3 -biotinylation for the cap-snatching assay A short biotinylated Cap 1-RNA (m 7 G-pppGm-RNA) was synthesized to screen candidate agents that inhibit influenza virus cap-snatching activity, which is shown schematically in Fig. 1 . An RNA (GACU 32 -biot) was prepared by in vitro transcription using T7 RNA polymerase and biotin-16-UTP, and the full-length product was separated from the prematurely terminated products by C 18 reverse-phase cartridge column chromatography. The Cap 1 structure was then added to GACU 32 -biot using recombinant enzymes, which were expressed in and purified from E. coli as His-tagged proteins, as described below.
A DNA template for T7 RNA polymerase transcription was designed to contain a short stretch of "A" residues 11-13 nucleotides from the transcription start site, because the influenza virus polymerase prefers "A" residues around the cleavage site of the cap-snatching reaction (Wakai et al., 2011) (Fig. 1) . As a general property, T7 RNA polymerase synthesizes 10-to 20-fold more prematurely terminated products (2-3 nucleotides long) than full-length RNA (Milligan and Uhlenbeck, 1989) . Therefore, a C 18 reverse-phase cartridge column was used to remove the prematurely terminated RNAs, which strongly inhibit the capping reaction (see Section 4). Fig. 2 shows a typical result of RNA purification. [␣-32 P]GTP (400 cpm/pmol) was included in the transcription reaction to monitor the distribution of RNAs during subsequent chromatography. As described above, the products of in vitro transcription contained masses of prematurely terminated RNAs besides the full-length GACU 32 -biot. Under the electrophoretic conditions (7 M urea/18% PAGE), free [␣-32 P]GTP moved faster than bromophenol blue (BPB), and the position of BPB was slightly lower than that of prematurely terminated RNAs (Fig. 2) . GACU 32 -biot bound strongly to the column in a solution containing 50 mM ammonium bicarbonate (pH 8.0), whereas the prematurely terminated RNAs bound negligibly to Fig. 2 . Purification of GACU32-biot. The product of in vitro transcription (input) was purified with C18 reverse-phase cartridge column chromatography. After the column was washed with 50 mM ammonium bicarbonate (pH 8.0), the column was developed with a stepwise increase in the CH3CN concentration. Each fraction was analyzed by 18% polyacrylamide gel electrophoresis in the presence of 7 M urea, and the RNAs were visualized by an image analyzer input, 1/1000 of the applied material; unbound, 1/1000 of the unbound fraction; 2%, 4% and 5%, 1/100 of the eluates; 6%, 8% and 10%, 1/20 of the eluates.
it. After washing the column with 50 mM ammonium bicarbonate, the column was developed by a stepwise increase in acetonitrile (CH 3 CN) concentration from 2 to 10%. The fractions containing GACU 32 -biot but not premature RNAs were lyophilized, and then subjected to the capping reaction.
Synthesis of Cap 1-RNA (m 7 GpppGm-RNA) for the cap-snatching assay
Because the influenza type A virus cap-dependent endonuclease prefers RNA containing Cap 1 (m 7 GpppNm-RNA) as a substrate over RNA containing Cap 0 (m 7 GpppN-RNA), it was necessary to convert the purified RNA into Cap 1-RNA. Four reactions are required for the synthesis of the Cap 1 structure (Fig. 1) . As described in Section 2, the N-terminal region of the vaccinia virus D1R subunit (D1N, amino acid residues 1-536, RNA 5 -triphosphatase and mRNA guanylyltransferase), S. cerevisiae ABD1 ([guanine-N-]-methyltransferase), and vaccinia virus VP39 ([nucleoside-2 -O-]-methyltransferase) as His-tagged proteins were expressed in E. coli and purified them by sequential column chromatography on Ni-NTA agarose and SP Sepharose. The purified enzymes were analyzed by 10% SDS-polyacrylamide gel electrophoresis and the proteins were visualized by Coomassie Brilliant Blue staining (Fig. 3) . All three enzymes were purified to near homogeneity and were free of detectable nuclease and phosphatase activities (data not shown).
GACU 32 -biot was incubated with the indicated enzymes (D1N, ABD1, and VP39) for 60 min at 37 • C (Fig. 4) , as described in Section 2, except that nonradioactive GTP was used to monitor the cap synthesis. Each product was digested with nuclease P1, which hydrolyzes all phosphodiester bonds of single-stranded RNA (generating 3 -hydroxyl ends), except those in the cap structure (Fig. 4A) . The resulting products were analyzed by thinlayer chromatography on polyethyleneimine-cellulose with 0.3 M ammonium sulfate as the solvent (Fig. 4B) . As expected, the pppG terminus of GACU 32 -biot (lane 1) was converted to GpppG by D1N (lane 2), then to m 7 GpppG by ABD1 (lane 3), and finally to m 7 GpppGm by VP39 (lane 4), with nearly a complete efficiency. To synthesize the substrate RNA for the cap-snatching assay, highly radioactive [␣-32 P]GTP (2 × 10 5 cpm/pmol, specific activity 500-fold higher than that used to label GACU 32 -biot) was used to label the Cap 1 structure. Fig. 4 . Synthesis and analysis of Cap 1-GACU32-biot. (A) Three sequential reactions were used to convert the triphosphate end of GACU32-biot to produce Cap 1-GACU32-biot. Each product was digested with nuclease P1 (which hydrolyzes all phosphodiester bonds, except those in Cap, represented by "slash" symbols), and the resulting products were analyzed by thin-layer chromatography on polyethyleneimine-cellulose with 0.3 M ammonium sulfate as the solvent. The asterisks represent the radioactive phosphates. In this experiment, nonradioactive GTP was used in the capping reaction. SAM denotes S-adenosyl-l-methionine and (B) a representative result of the capping reaction with the indicated recombinant enzymes. After digestion with nuclease P1, the samples were analyzed by thin-layer chromatography, followed by autoradiography. 32 P]Cap 1-GACU32-biot (50 fmol) was incubated with increasing amounts (0.25-1.25 g) of influenza virus A virions. The products of the reaction were divided into two equal samples. One was analyzed on 18% polyacrylamide gel with 7 M urea, followed by autoradiography (A). The endonuclease activity is expressed as the ratio of the amount of cleaved RNA to the amount of total capped RNA. The second sample was subjected to the pull-down assay, as described in Section 2. The unbound and bound fractions were quantified separately by measuring the Cerenkov radiation. The ratios of cleaved RNA determined by gel electrophoresis (open circles) and by the pull-down assay (closed circles) are shown. Typical results of three independent experiments are shown.
Cap-snatching assay
[ 32 P]Cap 1-GACU 32 -biot was tested to determine whether it is a substrate of the influenza virus cap-snatching activity (Fig. 5) . Two methods were employed to measure cap-snatching activity: one was 18% polyacrylamide gel electrophoresis in the presence of 7 M urea; and the other was a novel pull-down method established in this study, based on the streptavidin-biotin interaction. [ 32 P]Cap 1-RNA was incubated with increasing amounts of the influenza type A virion in the presence of 0.1% Nonidet P-40. After the reaction, the reaction products were divided into two equal samples. One sample was analyzed by 18% denaturing polyacrylamide gel electrophoresis and autoradiography, clearly demonstrating that [ 32 P]Cap 1-RNA was a good substrate for the reaction (Fig. 5A ). In the pull-down assay, the radioactivity in the Cap 1 structure of GACU 32 -biot is trapped by streptavidin-conjugated beads before the cap-snatching reaction, whereas the radioactivity in the cleaved RNA after the cap-snatching reaction is recovered in the supernatant fraction. The second sample (the other half of the cap-snatching reaction products) was mixed with paramagnetic streptavidin-conjugated Dynabeads ® , and the unbound and bound fractions were separated and quantified as described in Section 2. The cap-snatching activity measured with the pull-down assay correlated well with that evaluated by gel electrophoresis (Fig. 5B) , demonstrating the reliability of the novel pull-down assay.
A known inhibitor of the cap-snatching reaction, 2-hydroxy-4-oxo-4-phenyl-2-butenoic acid (compound 5 of (Tomassini et al., 1994) , was tested with the pull-down method. This compound showed an IC 50 value of 65 M, which is close to the value described in the literature (Tomassini et al., 1994) , confirming the efficacy of the pull-down assay system (Fig. 6 ).
Discussion
In this study, an efficient screening system for inhibitors of influenza virus cap-snatching activity was established. A short RNA with 3 -biotinylation was synthesized using T7 RNA polymerase, purified by C 18 reverse-phase column chromatography, and capped with three recombinant enzymes. This Cap 1-RNA was shown to be a good substrate for the influenza virus cap-snatching activity. A convenient streptavidin-biotin-based pull-down assay to measure this cap-snatching activity was also developed.
To screen a large number of compounds, it is essential to synthesize the substrate RNA with the Cap 1 structure in large quantities and in a homogeneous state with respect to its cap structure and the length of the RNA. In previous studies, the Cap 1-RNA substrate was prepared by capping previously decapped alfalfa mosaic virus RNA with [␣-32 P]GTP (Tomassini et al., 1994 (Tomassini et al., , 1996 Hsu et al., 2012) . However, it is difficult to prepare natural RNAs in large quantities. Therefore, this procedure may not be suitable for large-scale screening.
The substrate RNA was synthesized by in vitro transcription with T7 RNA polymerase. However, as a general property, T7 RNA polymerase synthesizes 10-to 20-fold more prematurely terminated products (2-3 nucleotides long) than full-length RNAs (Fig. 2 ) (Milligan and Uhlenbeck, 1989) , and these may competitively inhibit the capping of the full-length RNA. Indeed, when the in vitrotranscribed RNA was subjected to the capping reaction without purification, more than half the cap structures were Cap 0 (data not shown). Polyacrylamide gel electrophoresis under denaturing conditions has been used to purify the full-length RNA (Milligan and Uhlenbeck, 1989; Tomassini et al., 1994 Tomassini et al., , 1996 Hsu et al., 2012) , but the yield from the polyacrylamide gel was generally low. Therefore, the full-length RNA (GACU 32 -biot) was purified by C 18 reversephase cartridge column chromatography. By increasing the CH 3 CN concentration in a stepwise manner, GACU 32 -biot was separated completely from the prematurely terminated products (Fig. 2) .
The full-length RNA (GACU 32 -biot) was subjected to the capping reaction using recombinant enzymes. cDNA expression plasmids for vaccinia virus DIR, as RNA 5 -triphosphatase and mRNA guanylyltransferase, S. cerevisiae ABD1 as (guanine-N-)-methyltransferase, and vaccinia virus VP39 as (nucleoside-2 -O-)-methyltransferase were constructed. These proteins were expressed in E. coli and purified to near homogeneity without detectable RNase activity (data not shown). The concentrations of the capping enzymes were set so that each step proceeded nearly stoichiometrically (Fig. 4) . Under the optimal conditions, 1 nmol of Cap 1-GACU 32 -biot was easily synthesized, which was enough for 10,000 assays.
When the RNA substrate to be capped contained a lot of premature products, as described above, or when the capping reaction was performed using insufficient enzymes, intermediate products containing Cap 0 or the core Cap were present (data not shown). Therefore, it is obviously necessary to analyze the cap structure by nuclease Pl digestion, followed by thin-layer chromatography, as we did in this study, to guarantee the homogeneity of the RNA substrate. However, in most preceding studies, the homogeneity of the cap structure was not assessed. Enzymological studies are necessary to develop a good inhibitor of cap-snatching. For such studies, the homogeneity of the substrate may be a critical requirement.
Successful GACU 32 -biot purification and subsequent capping of the purified RNA with a high yield allowed us to establish a streptavidin-biotin-based pull-down assay for the cap-snatching activity. In this assay, the radioactivity in the cap structure becomes detached from the streptavidin beads upon cap-snatching because the substrate RNA binds to the streptavidin beads through the 3 -terminal biotinylated UMP. Prematurely terminated RNAs, if present in the substrate, may cause background noise in the pulldown assay because these molecules do not bind to the streptavidin beads, regardless of the viral cap-snatching activity. Because the influenza type A virus prefers RNAs with the Cap 1 structure over those with the Cap 0 structure, it is also critical to add the Cap 1 structure to the substrate RNAs stoichiometrically. The procedure established in this study satisfies both of these critical requirements.
The pull-down assay developed in this study has several advantages over the traditional gel-based assay. First, the sample number could be easily increased, in contrast to the limited sample number of the gel-based assay. Ethanol precipitation that is necessary for gel-based assay to eliminate free [␣-32 P]GTP and to reduce volume of the samples is not necessary for the pull-down assay. Third, the pull-down assay takes much shorter time of period than gel-based assay, because the time for gel electrophoresis is not necessary. Furthermore, the pull-down assay could be automated in future by using magnetic beads or multi-titer well plate coated with streptoavidin.
In summary, an efficient method to synthesize a Cap 1-RNA substrate and a novel streptavidin-biotin-based pull-down assay that may dramatically increase the efficiency of screening for anti-capsnatching compounds have been established in this study, which may contribute to the development of novel anti-influenza drugs.
